HIMS241115P40000
- 0.00
- 0.000.00%
Hims & Hers Health Newsroom
BofA Securities Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Cuts Target Price to $18
Peering Into Hims & Hers Health's Recent Short Interest
Hims & Hers Health(HIMS.US) Officer Sells US$4.28 Million in Common Stock
$Hims & Hers Health(HIMS.US)$ Officer Okupe Oluyemi sold 142.89K shares of common stock on Nov 13, 2024 at an average price of $29.9302 for a total value of $4.28 million.Source: Announcement What
S&P 500 Futures Fall In Premarket Trading; AST SpaceMobile, Applied Materials Lag
Hims & Hers Health Shares Rise in Premarket Trading After Amazon-Driven Slump Thursday
Hims & Hers Health Insider Sold Shares Worth $4,276,609, According to a Recent SEC Filing
Hims & Hers Health Options Spot-On: On November 14th, 274.11K Contracts Were Traded, With 497.81K Open Interest
On November 14th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 274.11K options for the day, of which put options accounted for 41.39% of the total
Small U.S. Stocks Drop; Hims & Hers Health Takes Biggest Hit
Sector Update: Health Care Stocks Weaker Late Afternoon
Sector Update: Health Care
Hims & Hers Cut to Underperform by BoA Over Amazon Competition
Hims & Hers Health Analyst Ratings
BofA Securities Downgrades Hims & Hers Health to Underperform From Buy
Hims & Hers Health Stock Is Tumbling Thursday: What's Going On?
Amazon Launches Fixed Pricing to Treat Conditions Like Hair Loss. Hims & Hers Stock Drops 15%
Hims & Hers Health Shares Are Trading Lower in Possible Response to Amazon's Introduction of Its Low Upfront Pricing Telehealth and Medication Plan.
Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 5.22 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 13, $Hims & Hers Health(HIMS.US)$ Officer Oluyemi Okupe intends to sell 189.15K shares of its common stock on Nov 13, with a total market value of approximately $5.22
Hims & Hers Launches GLP-1 Drug Shortage Tracker
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue